Terms: = Leukemia AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
184 results:
1. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract] [Full Text] [Related]
2. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Scott MT; Liu W; Mitchell R; Clarke CJ; Kinstrie R; Warren F; Almasoudi H; Stevens T; Dunn K; Pritchard J; Drotar ME; Michie AM; Jørgensen HG; Higgins B; Copland M; Vetrie D
Nat Commun; 2024 Jan; 15(1):651. PubMed ID: 38246924
[TBL] [Abstract] [Full Text] [Related]
3. mdm2-p53 mediate a miR-181c-3p/LIF axis to regulate low dose-rate radiation-induced DNA damage in human B lymphocytes.
Chen Y; Gong Y; Qin H; Wei S; Wei Y; Yu Y; Lin X; Shuai P; Wang T; Guo C; Wang Q; Li G; Meng L; Yi L
Ecotoxicol Environ Saf; 2024 Jan; 270():115848. PubMed ID: 38134636
[TBL] [Abstract] [Full Text] [Related]
4. A GPX4 non-enzymatic domain and mdm2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis induction.
Niu F; Yang R; Feng H; Liu Y; Liu R; Ma B
Biochem Biophys Res Commun; 2023 Dec; 684():149125. PubMed ID: 37897912
[TBL] [Abstract] [Full Text] [Related]
5. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract] [Full Text] [Related]
6. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction.
Gasparoli L; Virely C; Tsakaneli A; Che N; Edwards D; Bartram J; Hubank M; Pal D; Heidenreich O; Martens JHA; De Boer J; Williams O
Haematologica; 2024 Apr; 109(4):1069-1081. PubMed ID: 37794795
[TBL] [Abstract] [Full Text] [Related]
7.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract] [Full Text] [Related]
8. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Senapati J; Muftuoglu M; Ishizawa J; Abbas HA; Loghavi S; Borthakur G; Yilmaz M; Issa GC; Dara SI; Basyal M; Li L; Naqvi K; Pourebrahim R; Jabbour EJ; Kornblau SM; Short NJ; Pemmaraju N; Garcia-Manero G; Ravandi F; Khoury J; Daver N; Kantarjian HM; Andreeff M; DiNardo CD
Blood Cancer J; 2023 Jun; 13(1):101. PubMed ID: 37386016
[TBL] [Abstract] [Full Text] [Related]
9. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
10. Combined inhibition of XIAP and autophagy induces apoptosis and differentiation in acute myeloid leukaemia.
Huang Z; Zhou J; Jiang Y; Han Y; Wang X; Li F; Jiang S; Yu K; Zhang S
J Cell Mol Med; 2023 Jun; 27(12):1682-1696. PubMed ID: 37154878
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis and biological evaluation of dual mdm2/XIAP inhibitors based on the tetrahydroquinoline scaffold.
Albadari N; Xie Y; Liu T; Wang R; Gu L; Zhou M; Wu Z; Li W
Eur J Med Chem; 2023 Jul; 255():115423. PubMed ID: 37130471
[TBL] [Abstract] [Full Text] [Related]
12. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
[TBL] [Abstract] [Full Text] [Related]
13. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic mdm2 Inhibition.
Aptullahoglu E; Ciardullo C; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768733
[TBL] [Abstract] [Full Text] [Related]
14. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
Salomao N; Maslah N; Giulianelli A; Drevon L; Aguinaga L; Gu X; Cassinat B; Giraudier S; Fenaux P; Fahraeus R
Br J Haematol; 2023 Apr; 201(2):234-248. PubMed ID: 36546586
[TBL] [Abstract] [Full Text] [Related]
15. An mdm2 degrader for treatment of acute leukemias.
Marcellino BK; Yang X; Ümit Kaniskan H; Brady C; Chen H; Chen K; Qiu X; Clementelli C; Herschbein L; Li Z; Elghaity-Beckley S; Arandela J; Kelly B; Hoffman R; Liu J; Xiong Y; Jin J; Shih AH
Leukemia; 2023 Feb; 37(2):370-378. PubMed ID: 36309559
[TBL] [Abstract] [Full Text] [Related]
16. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.
Sekiguchi N; Kasahara S; Miyamoto T; Kiguchi T; Ohno H; Takagi T; Tachibana M; Sumi H; Kakurai Y; Yamashita T; Usuki K
Int J Hematol; 2023 Jan; 117(1):68-77. PubMed ID: 36258088
[TBL] [Abstract] [Full Text] [Related]
17. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid leukemia and Acute Lymphoblastic leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract] [Full Text] [Related]
18. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract] [Full Text] [Related]
19. Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.
Emdal KB; Palacio-Escat N; Wigerup C; Eguchi A; Nilsson H; Bekker-Jensen DB; Rönnstrand L; Kazi JU; Puissant A; Itzykson R; Saez-Rodriguez J; Masson K; Blume-Jensen P; Olsen JV
Cell Rep; 2022 Aug; 40(6):111177. PubMed ID: 35947955
[TBL] [Abstract] [Full Text] [Related]
20. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract] [Full Text] [Related]
[Next]
